New clinical trial : in vivo assessment of silver biomaterial nanotoxicity


University of Utah will launch a phase I / phase II clinical trial to assess silver biomaterial nanotoxicity in healthy human volunteers, registered in the Clinicaltrials.gov database under reference NCT01243320. The purpose of the trial is to :

- quantify comprehensive metabolic panel, urinalysis, and CBC with platelet count changes from exposure to 10 ppm silver solution ;

-quantify silver in whole blood and urine by measurement of silver metallic ions (Ag0) ;

-quantify granulocyte and agranulocyte counts, measuring presence of reactive oxygen species (ROS), and determining presence of pro-inflammatory genetic markers from induced sputum ;

-qualify silver nanoparticle retention in human organ systems (on the last day of each phase of the study, all eligible subjects without will undergo a cardiac and abdominal MRI to identify retention Ag0 nanoparticles).

The study is not yet open for participant recruitment.

[[[ Additional links suggested by Nanocolors :

# Silver nanoparticles in biomedical publications since 2000

# Nanomaterials and toxicity in biomedical publications since 2000 ]]]

About these ads

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Follow

Get every new post delivered to your Inbox.

%d bloggers like this: